Concerns about pharmaceutical safety testing cause clinicians to appeal to UK PM and Health Sec

10 June 2011

A group of eminent UK clinicians and scientists who have written an open letter to Prime Minister David Cameron and Health Secretary Andrew Lansley expressing concerns about the escalating problems of drug failures and adverse drug reactions. Adverse drug reactions have reached epidemic proportions amid rising costs in prescriptions, with around 197,000 EU citizens dying every year because of the problem.

The letter, published 3 June 2011 in the medical journal, The Lancet, says the reliance on testing new drugs on animals before humans is partly to blame, with trials on non-humans frequently failing to translate to the clinic. The experts have called for the use of more human-biology-based experiments where chemicals are tested on human cells to see how people might be affected by new treatments.

Adverse drug reactions have reached epidemic proportions and are increasing at twice the rate of prescriptions, the letter points out. The European Commission estimated in 2008 that adverse reactions kill 197 000 EU citizens annually, at a cost of 79 billion euros ($115 billion).The cost of new medicines is rising unsustainably, creating an ever-increasing burden on the National Health Service (NHS). Meanwhile, many increasingly prevalent diseases, such as Alzheimer's disease, diabetes, many cancers, and stroke, remain without adequate treatments, it was noted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical